Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Background and Purpose</h3><p>Adiponectin (APN) is an adipokine secreted from adipocytes that binds to adiponectin receptors AdipoR1 and AdipoR2 and exerts an anti‐inflammatory response through mechanisms not fully understood. There is a need to develop small molecules that activate AdipoR1 and AdipoR2 and to be used to inhibit the inflammatory response in lipopolysaccharide (LPS)‐induced endotoxemia and other inflammatory disorders.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Experimental Approach</h3><p>We designed 10 new structural analogs of an AdipoR agonist, AdipoRon (APR) and assessed their anti‐inflammatory properties. Bone marrow‐derived macrophages (BMMs) and peritoneal macrophages (PEMs) were isolated from mice. Levels of pro‐inflammatory cytokines were measured by qRT‐PCR, ELISA and microarray in LPS‐induced endotoxemia mice and diet‐induced obesity (DIO) mice in which systemic inflammation prevails. Western blotting, immunohistochemistry (IHC), siRNA interference and immunoprecipitation were used to detect signaling pathways.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Key Results</h3><p>A novel APN receptor agonist named AdipoAI strongly suppresses inflammation in DIO and endotoxemia mice, as well as in cultured macrophages. We also found that AdipoAI attenuated the association of AdipoR1 and APPL1 via myeloid differentiation marker 88 (MyD88) signaling, thus inhibiting activation of nuclear factor kappa B (NF‐κB), mitogen‐activated protein kinase (MAPK) and c‐Maf pathways and limiting the production of pro‐inflammatory cytokines in LPS‐induced macrophages.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusion and Implications</h3><p>AdipoAI is a promising alternative therapeutic approach to APN and APR to suppress inflammation in LPS‐induced endotoxemia and other inflammatory disorders via distinct signaling pathways.</p></section>

Adipose specific aptamer adipo-8 recognizes and interacts with APMAP to ameliorates fat deposition <i>in vitro</i> and <i>in vivo</i>

Adipo8, a high-affinity DNA aptamer, can differentiate among adipocytes and inhibit intracellular lipid accumulation in vitro

Therapeutic of a White Adipose Tissue-Specific Bivalent Aptamer in Obesity

Selection Of Aptamers Specific For Adipose Tissue

Targeted delivery of emodin to adipocytes by aptamer-functionalized PEG-PLGA nanoparticles in vitro

Therapeutic potential of a synthetic FABP4 inhibitor 8g on atherosclerosis in ApoE-deficient mice: the inhibition of lipid accumulation and inflammation

Aptamer-functionalized liposome delivery system targeting adipose for hypereffective obesity therapy

Identification and characterization of a novel adiponectin receptor agonist adipo anti‐inflammation agonist and its anti‐inflammatory effects in vitro and in vivo

Aptamer-Functionalized Binary-Drug Delivery System for Synergetic Obesity Therapy

Apolipoprotein A1 Inhibits Adipogenesis Progression of Human Adipose-Derived Mesenchymal Stem Cells

Antidiabetic features of AdipoAI, a novel AdipoR agonist

A Novel Peptide Suppresses Adipogenic Differentiation Through Activation of the AMPK Pathway.

Hyperlipidemic Plasma Molecules Bind and Inhibit Adiponectin Activity

Synthesis and Biological Evaluation of Novel Bouchardatine Derivatives As Potential Adipogenesis/Lipogenesis Inhibitors for Antiobesity Treatment

The Mab Against Adipocyte Fatty Acid-Binding Protein 2E4 Attenuates the Inflammation in the Mouse Model of High-Fat Diet-Induced Obesity Via Toll-Like Receptor 4 Pathway.

Small molecule inhibitors of human adipocyte fatty acid binding protein (FABP4).

Angptl8 antisense oligonucleotide improves adipose lipid metabolism and prevents diet-induced NAFLD and hepatic insulin resistance in rodents

Apelin Inhibits Adipogenesis and Lipolysis Through Distinct Molecular Pathways

Apolipoprotein A-IV Restrains Fat Accumulation in Skeletal and Myocardial Muscles by Inhibiting Lipogenesis and Activating PI3K-AKT Signalling.

Annonaceous acetogenins mimic AA005 targets mitochondrial trifunctional enzyme a subunit to treat obesity

Obesity-related metabolic disorders mitigated by peptides designed to modulate adiponectin assembly.